ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026
Prognosis of increasing percentages of lesional body surface area in early stage mycosis fungoides.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Diagnostic delay in mycosis fungoides: Insights from China's first multicentre registry of 305 patients.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- The dual burden of a rare cancer: psychosocial impact of disease symptoms and unmet care needs in cutaneous T-cell lymphoma.Frontiers in psychology · 2026Article
- Prognosis of increasing percentages of lesional body surface area in early stage mycosis fungoides.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Beyond surface: Rethinking prognostic boundaries in early mycosis fungoides.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- The diagnosis of early-stage mycosis fungoides: Views held by experts and non-experts in cutaneous lymphoma.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEarly-stage mycosis fungoides (MF) is often an indolent disease with a favourable prognosis, though 25% progress to advanced stages. Patients with ≥10% body surface area (BSA) involvement have a worse prognosis than those with <10%, but the impact of other BSA levels remains unclear.
objectivesThis study aimed to determine whether additional BSA cut-off points higher than 10% provide additional prognostic information.
methodsThis study included 401 patients with early-stage MF of the Leiden University Medical Centre and a validation cohort of 602 patients from the PROCLIPI database. Different percentages of lesional BSA were analysed both in the total groups and in subgroups of patients with only patch-stage disease or with patch-plaques-stage disease, and correlated with survival.
resultsBoth cohorts showed a progressive and gradual decline in overall survival (OS) with each 10% increase in BSA, reaching a 5-year OS below 50% (LUMC) or 70% (PROCLIPI) for BSA ≥40%. In both cohorts, patients with a BSA of 10%-39% had a significantly worse OS than those with a BSA of less than 10%, but a significantly better OS than those with ≥40%. These differences in OS were only found in patients with patches and plaques and not in patients with only patches.
conclusionsAn additional cut-off point of 40% involved BSA has prognostic significance in patients with early patch/plaque-stage MF and may be included in future updates of the clinical staging system. In these patients, systemic therapies should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.